Here are the DEF 14A proxy statements from Coherus Oncology, Inc. (CHRS) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow CHRS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CHRS filings page.
Coherus Oncology, Inc. is asking stockholders to vote at its virtual 2026 annual meeting on director elections, auditor ratification, executive pay, a one-time stock option repricing and a larger equity incentive pool. Holders of 154,217,609 common shares as of April 16, 2026 may vote online or by proxy.
Stockholders will elect two Class III directors, ratify Ernst & Young LLP as independent auditor for 2026, and cast an advisory “say‑on‑pay” vote on named executive officer compensation. They are also being asked to approve reducing the exercise price and extending the term of 9,540,140 underwater employee and consultant options, and to add 7,700,000 shares to the Amended and Restated 2014 Equity Incentive Award Plan.
The board, which is majority independent and organized into audit, compensation, and nominating/governance committees, recommends voting “FOR” all five proposals, including the equity plan amendment intended to preserve stock‑based incentives as a core element of compensation and retention.